147 related articles for article (PubMed ID: 37773473)
1. Clinical characterization, treatment, and outcome of nivolumab-induced bullous pemphigoid.
Liu M; Yuan M; Sun W; Li Z; Zhou X; Wang C
Invest New Drugs; 2023 Dec; 41(6):802-807. PubMed ID: 37773473
[TBL] [Abstract][Full Text] [Related]
2. Bullous Pemphigoid Masquerading as Erythema Annulare Centrifugum.
Yu-Yang S; Chu-Sung Hu S; Yiao-Lin S
Acta Dermatovenerol Croat; 2017 Oct; 25(3):255-256. PubMed ID: 29252183
[TBL] [Abstract][Full Text] [Related]
3. Childhood bullous pemphigoid: a clinicopathologic study and review of the literature.
Fisler RE; Saeb M; Liang MG; Howard RM; McKee PH
Am J Dermatopathol; 2003 Jun; 25(3):183-9. PubMed ID: 12775979
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab-induced localized genital bullous pemphigoid in a 60-year-old male.
Alvarado SM; Weston G; Murphy MJ; Stewart CL
J Cutan Pathol; 2022 May; 49(5):468-471. PubMed ID: 34881446
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid.
Wang J; Hu X; Jiang W; Zhou W; Tang M; Wu C; Liu W; Zuo X
Front Oncol; 2023; 13():1095694. PubMed ID: 36937423
[TBL] [Abstract][Full Text] [Related]
6. A case of nivolumab-induced bullous pemphigoid successfully treated with dupilumab.
Bruni M; Moar A; Schena D; Girolomoni G
Dermatol Online J; 2022 Mar; 28(2):. PubMed ID: 35670683
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the Clinical Characteristics of Dipeptidyl Peptidase-4 Inhibitor-Induced Bullous Pemphigoid.
Sun L; Wang C; Wu C; Zhou Y; Wang C
Ann Pharmacother; 2022 Feb; 56(2):205-212. PubMed ID: 34105395
[TBL] [Abstract][Full Text] [Related]
8. A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy.
Guan S; Zhang L; Zhang J; Song W; Zhong D
Front Immunol; 2022; 13():1068978. PubMed ID: 36685586
[TBL] [Abstract][Full Text] [Related]
9. Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature.
Klepper EM; Robinson HN
Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755978
[TBL] [Abstract][Full Text] [Related]
10. Concomitant nivolumab-associated Grover disease and bullous pemphigoid in a patient with metastatic renal cell carcinoma.
Khazaeli M; Grover R; Pei S
J Cutan Pathol; 2023 Jun; 50(6):520-523. PubMed ID: 36601731
[TBL] [Abstract][Full Text] [Related]
11. Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma: A case report of abscopal toxicities.
Huynh LM; Bonebrake BT; DiMaio DJ; Baine MJ; Teply BA
Medicine (Baltimore); 2021 Dec; 100(49):e28199. PubMed ID: 34889301
[TBL] [Abstract][Full Text] [Related]
12. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G
Front Immunol; 2022; 13():984132. PubMed ID: 36189265
[TBL] [Abstract][Full Text] [Related]
13. Bullous pemphigoid.
Miyamoto D; Santi CG; Aoki V; Maruta CW
An Bras Dermatol; 2019; 94(2):133-146. PubMed ID: 31090818
[TBL] [Abstract][Full Text] [Related]
14. Non-Bullous Pemphigoid: A Single-Center Retrospective Study.
Moar A; Azzolini A; Tessari G; Schena D; Girolomoni G
Dermatology; 2021; 237(6):1039-1045. PubMed ID: 33979792
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study.
Kawsar A; Edwards C; Patel P; Heywood RM; Gupta A; Mann J; Harland C; Heelan K; Larkin J; Lorigan P; Harwood CA; Matin RN; Fearfield L
Br J Dermatol; 2022 Dec; 187(6):981-987. PubMed ID: 35976170
[TBL] [Abstract][Full Text] [Related]
16. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
Aggarwal P
Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310
[No Abstract] [Full Text] [Related]
17. A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial.
Chalmers JR; Wojnarowska F; Kirtschig G; Mason J; Childs M; Whitham D; Harman K; Chapman A; Walton S; Schmidt E; Godec TR; Nunn AJ; Williams HC
Health Technol Assess; 2017 Mar; 21(10):1-90. PubMed ID: 28406394
[TBL] [Abstract][Full Text] [Related]
18. An infant with bullous pemphigoid.
Santos AL; Mota AV; Ramon J; Lopes JM; Azevedo F
Dermatol Online J; 2007 Jul; 13(3):17. PubMed ID: 18328211
[TBL] [Abstract][Full Text] [Related]
19. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors.
Lopez AT; Khanna T; Antonov N; Audrey-Bayan C; Geskin L
Int J Dermatol; 2018 Jun; 57(6):664-669. PubMed ID: 29630716
[TBL] [Abstract][Full Text] [Related]
20. Localized pemphigoid on the soles of both feet.
Forschner A; Fierlbeck G
Int J Dermatol; 2005 Apr; 44(4):312-4. PubMed ID: 15811084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]